TD Cowen has designated Agios Pharmaceuticals as one of its "best ideas" within the biotechnology sector, highlighting two primary drivers: unexpectedly strong early demand for the company’s thalassemia treatment Aqvesme and promising developments for tebapivat in sickle cell disease.
The research note emphasizes that Aqvesme’s initial uptake appears to be underappreciated by the market and could generate significant value independently of later-stage pipeline outcomes. TD Cowen reported 242 Aqvesme prescriptions written by the end of the first quarter, a sharp increase from 44 prescriptions as of January 31. Using those prescription levels, the firm estimates an annualized demand figure of roughly $82 million after applying a 20% gross-to-net adjustment.
That projection notably exceeds consensus estimates for 2026. TD Cowen contrasted the $82 million annualized figure with the pre-earnings 2026 consensus of about $44 million and the post-earnings 2026 consensus of around $63 million. In the firm’s own modeling, 2026 U.S. thalassemia sales are projected at $79 million.
TD Cowen’s analysis of the thalassemia opportunity assumes the approved label covers more than 4,000 U.S. patients who have high transfusion needs and significant symptom burdens, making them appropriate candidates for therapy. From that patient pool, the firm calculates a U.S. total addressable market of $1.7 billion, observing that roughly 20% of global thalassemia patients reside in the United States.
Based on the thalassemia-driven valuation, TD Cowen suggested Agios shares are worth at least $42, applying a modest 35% peak penetration assumption. The firm also flagged the company’s sickle cell franchise as a potential additional upside source if pipeline milestones are achieved.
Specifically, TD Cowen noted the importance of upcoming Phase 2 data for tebapivat, which the firm expects to be reported in the second half of 2026. The research house views that data as an event capable of materially improving investor sentiment toward Agios’ position in the emerging multi-billion dollar category of PKR activation in sickle cell disease.
TD Cowen referenced existing clinical evidence suggesting tebapivat delivers superior hemoglobin benefits compared with both mitapivat and etavopivat, which in the firm’s view could position tebapivat as a long-term frontrunner among PKR activators for sickle cell disease if clinical outcomes continue to support that profile. The firm also noted that positive data from Novo’s etavopivat has shaped expectations in this space and that tebapivat’s Phase 2 outcome may reverse or reinforce those expectations.
The research note covered a set of recent corporate developments as well. Agios announced it would discontinue development of tebapivat for lower-risk myelodysplastic syndromes following a trial setback. Separately, the company reported positive Phase 3 results for mitapivat in sickle cell disease and completed a licensing agreement to acquire rights to cevidoplenib from Oscotec.
Market context and analyst view
TD Cowen’s combination of stronger-than-anticipated commercial traction for Aqvesme and the potential for a meaningful positive readout from tebapivat in the second half of 2026 underpins its designation of Agios as a top idea in biotechnology. The firm’s modeling ties current prescription trends to an increased near-term revenue outlook while preserving the upside tied to successful sickle cell program data.